-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Based on the significant improvement in overall survival (OS), the Phase III CHAARTED trial identified pre-androgen deprivation therapy (ADT) combined with docetaxel (D) as the standard treatment for metastatic hormone-sensitive prostate cancer (mHSPC)
.
At present, the markers/factors that can predict the benefit of chemotherapy and clinical prognosis of patients are not clear
Hamid et al.
collected primary prostate cancer (PC) tissues for full transcriptome analysis of patients recruited in the CHAARTED trial before systemic treatment, and adopted a priori analysis plan to test predetermined RNA characteristics and their clinical phenotypes with HSPC Correlation with prognosis
.
Multivariate analysis (MVA) was adjusted according to age, ECOG status, new metastasis manifestations, tumor size, and treatment group
A total of 160 patients with primary PC were included
.
Compared with localized PC, primary PC showed a significantly different transcription profile, mainly luminal B (50%) and basal cell subtype (48%), low AR activity (AR-A) and high risk of Decipher
In the multivariate analysis, higher Decipher risk and lower AR-A were significantly associated with poorer OS
.
In addition, the higher Decipher risk is more related to the OS benefit of patients treated with ADT+D (HR 0.
Both higher Decipher risk and lower AR-A are significantly associated with poorer OS
In summary, the results of this study show that transcriptomics subtypes have the utility of guiding the prognosis of mHSPC patients and chemotherapy choices, and provide a proof of concept for the possibility of using biomarkers to guide mHSPC patients to choose treatment options
Transcriptomics subtypes have the utility of guiding the prognosis of mHSPC patients and chemotherapy choices, and provide a proof of concept for the possibility of using biomarkers to guide mHSPC patients to choose treatment options.
Original source:
Hamid AA,Huang HC,Wang V et al.
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED study in this message
